In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
-
Must-Know FDA Guidance Documents from 2017
A thought-leadership piece co-authored by Cynthia Nolte, Sandra D. Maher, and Ashleigh Dawley on the new and updated guidance documents issued by the FDA in 2017, focusing on those important formedical manufacturersand the industry.
-
Putting Patients to the Forefront
Featuring commentary from Tom O’Leary in an Irish Times article on the potential of digital technology to create a new patient-centric business model.
-
Access and Reimbursement for Adoptive T-Cell Transfer Drugs
ICON experts inoncology and pricing & market accessshare their thoughts on offsetting payer obstacles in this Pharmaceutical Executive article.
-
Patient Recruitment Tool to Improve Sponsor Visibility
ICON has launched a new digital solution aimed at increasing the efficiency and quality ofpatient eligibility assessments to support clinical trial recruitment.
-
Europes New Medical Device Rules
Learn how you can avoid the expected delays and extra costs in your development process underMDR and IVDR Medical Device Regulations.
-
Bringing Precision Medicine to Traumatic Brain Injury Treatment
An article reporting on ICON's contribution to a complex pan-European traumatic brain injury (TBI) research study.
-
Trending 2018: What Does the Future Hold?
Trending 2018: What Does the Future Hold?- featuring commentary from PV100 honouree Bill Byrom, on prevailing trends in the industry.
-
Building a Comprehensive Real World Evidence Strategy
ICON’s Jim Carroll outlines how a fully integrated, multidisciplinary RWE model can save time, money and effort in study development and execution, for better commercial outcomes.
-
A Rare Journey: Managing the Regulatory Landscape
ICON contributes to this article in PharmaVOICE looking at efforts undertaken to progress the development ofrare disease drugs.
